Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.

doi:10.1158/1078-0432.CCR-23-4072

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.

Clinical cancer research : an official journal of the American Association for Cancer Research - 13 Sept 2024

Martínez-Quintanilla Jordi, Cabot Débora, Sabia Doménico, Arqués Oriol, Vergés Jordi, Chicote Irene, Bijelic Lana, Cabellos Laia, Alcántara Anna M, Ramos Isabel, Barrios Pedro, Crusellas Oriol, Palacio Lina M, Cámara Juan A, Barriuso Jorge, Jiménez Juan J, Muñoz-Torres Pau, Nonell Lara, Flores Raquel, Médico Enzo, Guaglio Marcello, Ros Javier, Élez Elena, Tabernero Josep, Aziz Omer, Deraco Marcello, Palmer Héctor G

Abstract excerpt

PURPOSE: Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains the mainstay of treatment but disease recurrence and death after relapse frequently occur in patients with PMP. New therapeutic strategies are therefore urgently needed for these patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Organoids

Share to Peritoneal Neoplasms

Share to Precision Medicine

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39018564
DOI: 10.1158/1078-0432.CCR-23-4072
PMCID: PMC11393541

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.PMID 39018564Read ↗

Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.Semantic proximity Read ↗

The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.Semantic proximity Read ↗

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.Semantic proximity Read ↗

Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.Semantic proximity Read ↗

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.Semantic proximity Read ↗

Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei.Semantic proximity Read ↗

Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.Semantic proximity Read ↗

Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell linesSemantic proximity Read ↗

Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.Semantic proximity Read ↗

Toward the molecular dissection of peritoneal pseudomyxoma.Semantic proximity Read ↗

Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome SequencingSemantic proximity Read ↗

Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.